Pediatric Pulmonology Research
The ASPEN Study
Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis – The ASPEN Study
Age: 14-85 years old
Sex at Birth: All
Sex at Birth: All
Type: Interventional Drug Study
Condition: Non-cystic fibrosis bronchiectasis (NCFBE)
Condition: Non-cystic fibrosis bronchiectasis (NCFBE)
Healthy Participants: No
Location: UH Cleveland Medical Center
Location: UH Cleveland Medical Center
Learn More About This Research Study
For more information, please email or call (216-286-9678) the study coordinator Aja Patterson, or complete the online form below.
Study Purpose
The purpose of this study is to evaluate the efficacy, safety, and tolerability of an experimental treatment, brensocatib, for NCFBE.
Who Can Participate
Participants between 14-85 years of age diagnosed with NCFBE may be eligible for this study.
- STUDY20201794
- NCT04594369